ArticleWorld journal of surgical oncology2026
Predicting survival of patients with spinal involvement in multiple myeloma using PATHFx 3.0 - a validation study of 100 patients in Germany.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal malignant lesions are a common feature in multiple myeloma (MM) and often require surgical intervention. Accurate survival prediction is critical for guiding treatment decisions in these patients. While PATHFx is a widely used, machine-learning-based prognostic tool for skeletal metastases, it has not been validated for malignant bone lesions in MM so far.
objectiveTo evaluate the predictive performance and clinical utility of PATHFx 3.0 in a well-characterized cohort of MM patients with spinal malignant lesions.
methodsA retrospective cohort of 100 MM patients with radiologically confirmed spinal malignant lesions treated between 2009 and 2024 at a tertiary care center was analyzed. 51 patients underwent surgery for the local treatment of spinal lesions, while 49 were treated with non-operative treatment regimes. Clinical data were entered into PATHFx 3.0 to generate survival estimates at 1, 3, 6, 12, 18, and 24 months. Model performance was assessed using Receiver Operating Curves (ROC) with Area under the Curve (AUC), Brier scores, calibration plots, and decision curve analysis (DCA), and compared to the actual survival in this cohort.
resultsPATHFx achieved good discriminatory performance at all time points, with AUC values ranging from 0.72 (1 month) to 0.79 (18 months). Calibration improved with longer prediction intervals, and Brier scores ranged from 0.09 to 0.20, with best accuracy at 3 months. DCA showed net clinical benefit for all models except the 1-month estimate. The inclusion of both surgical and non-surgical patients enhanced the generalizability of results.
conclusionPATHFx 3.0 is a reliable and clinically useful tool for survival estimation in MM patients with spinal disease. Its flexible design and acceptable predictive performance support its use in multidisciplinary treatment planning, especially where traditional scoring systems fall short.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.